ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

ClinicalTrials.gov ID: NCT02912949

Public ClinicalTrials.gov record NCT02912949. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

Study identification

NCT ID
NCT02912949
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Partner Therapeutics, Inc.
Industry
Enrollment
250 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2014
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026
Last update posted
Apr 28, 2025

2015 – 2026

United States locations

U.S. sites
26
U.S. states
17
U.S. cities
24
Facility City State ZIP Site status
Mayo Clinic Phoenix Arizona
The Oncology Institute of Hope and Innovation Cerritos California
University of California Irvine Irvine California
Stanford University Palo Alto California
Sharp Memorial Hospital San Diego California
Georgetown University Washington D.C. District of Columbia
Memorial Cancer Institute Hollywood Florida
Cancer Specialists of North Florida Jacksonville Florida
Mayo Clinic Jacksonville Florida
Emory Winship Cancer Institute Atlanta Georgia
Northwest Oncology & Hematology Rolling Meadows Illinois
Dana Farber Cancer Center Boston Massachusetts
Karmanos Cancer Center Detroit Michigan 48201
Mayo Clinic Rochester Minnesota
Billings Clinic Cancer Center Billings Montana
St. James Healthcare Butte Montana
Memorial Sloan Kettering Cancer Center New York New York
University of Pennsylvania Philadelphia Pennsylvania
Averra Medical Group Sioux Falls South Dakota
The University of Texas MD Anderson Cancer Center Houston Texas
Huntsman Cancer Institute Salt Lake City Utah
Utah Cancer Specialists Salt Lake City Utah
Hematology-Oncology Specialist of Fredericksburg Fredericksburg Virginia
Virginia Mason Hospital & Seattle Medical Center Seattle Washington
Hematology Oncology Associates Spokane Washington
Northwest Medical Specialties Tacoma Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02912949, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 28, 2025 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02912949 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →